14th ICID - Poster Abstracts - International Society for Infectious ...

More documents

Recommendations

Info

When citing these abstracts please use the following reference: Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number. Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1 is available electronically on http://www.sciencedirect.com Final Abstract Number: 83.015 Session: Vaccines and Vaccine Development Date: Thursday, March 11, 2010 Time: 12:30-13:30 Room: Poster & Exhibition Area/Ground Level Type: Poster Presentation Impact study of hepatitis B vaccination in Sikkim - A north eastern state of India A. VERMA, V. Gupta Sikkim Manipal Institute of Medical Sciences, Gangtok, SIKKIM, India Background: Sikkim is a small state of India which introduced hepatitis B vaccination into its immunization schedule. Sikkim is the first state of India to introduce Hepatitis vaccination in the year 2004. Hepatitis B coverage for the state of Sikkim is approximately 10,000 children per year and immunization is done at 6, 10 and 14 weeks of age. Booster dose has not been incorporated in the immunization schedule. Since the time of introduction of immunization no impact study has been done in the vaccinated children. Whether the children being vaccinated mount an adequate antibody response against the vaccine needs to be investigated. An attempt was made to study the anti-HBs levels in a cross sectional study of children who received the vaccination against Hepatitis B. Methods: 160 post vaccinated children and adolescents were included in the study. Only those who had completed three doses of the vaccination were included. Serum collected was tested using a commercially available sandwich ELISA kit. The quality control criteria were fulfilled and the data was analyzed. Anti-HBs Levels below 10mIU/ml were considered as non responders and levels above 10mIU/ml were considered as responders. Results: 53.1% of the participants were males and 46.9% were females. Analysis of data revealed that 64.4% of the population under study were responders and 35.6% were non responders. Female participants who were non responders were greater than males (38.6%: 32.9%). No significant relation between age and response was seen. Conclusion: The percentage of non-responders in the post vaccination children was significantly higher as compared to most studies conducted in other countries. No study has been done in India to see the impact of vaccination in children. Females seem to be non responders as compared to males contrary to some studies. Further studies need to be conducted to investigate the cause of this anomaly. Presuming that India is on the verge of introducing universal vaccination against HBV, preparedness to encounter the problem of non responders to vaccination needs to be addressed and a strategy developed to counter it.
When citing these abstracts please use the following reference: Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number. Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1 is available electronically on http://www.sciencedirect.com Final Abstract Number: 83.016 Session: Vaccines and Vaccine Development Date: Thursday, March 11, 2010 Time: 12:30-13:30 Room: Poster & Exhibition Area/Ground Level Type: Poster Presentation A vaccine derived poliovirus case in an immunocompromised argentinian child M. E. Burgos 1 , S. Elkik 1 , P. Barbosa 1 , M. Oleastro 1 , C. Freire 2 , A. Parra 1 , M. Caparelli 3 , C. Sarkis 4 1 Hospital Garrahan, Buenos Aires, Argentina, 2 Servicio de Neurovirosis Dpto. Virología . IENEI- NLIS “Dr. Carlos G. Malbran”, Buenos Aires, Argentina, 3 Ministerio de Salud, Buenos Aires, Argentina, 4 Hospital Garrahan , Capital Federal, Argentina, Argentina Background: Although poliomyelitis caused by wild-type poliovirus has been almost eradicated, especially in developed countries, vaccine associated paralytic poliomyelitis (VAPP) cases still continue to occur in Latin American countries. In Argentina, where OPV routine immunization policy is ongoing, the last wild poliovirus (WPV) case was registered in 1984. Since then, the several polio cases reported were VAPP and Vaccine Derived Poliovirus (VDPV) (first iVDPV case was detected in 1998). Methods: To report a polio case caused by a VDPV in an immunodeficient patient diagnosed with polyclonal agammaglobulinemia. Results: In May 2009 a 15 month-old patient was hospitalized in our institution for acute flaccid monoparesis in his left lower limb with areflexia, with residual paralysis 60 days after onset. The patient had a history of recurrent infections (sepsis meningitis and pneumonia).Vaccination calendar was completed for his age (DPt/Hib-HB & OPV: 3 doses). The child received OPV3, 8 months before. LCR 8 cells / prot 25 mg/100 mL / Glu 50 mg/ml with negative cultures (bacteria - mycobacterium, fungi). EMG showed pre-ganglionic injury. Spine MRI showed focal intramedullary cone and lower thoracic spinal cord with hyperintense signal in T2 left hemicord. The major capsid protein (VP1) of the Sabin virus T1 isolated in feces showed a 96.5% genetic similarity to Sabin 1 vaccine strain (a 3.5% genetic divergence in this region). Conclusion: The occurrence of iVDPVs appears to be very rare; the majority of patients stopped excretion of the virus after a certain period or have died. The overriding factor for the emergence of all VDPVs is the same as for WPV circulation, i.e., low routine OPV coverage rates in children. Thus, a community can become susceptible to the emergence of all types of VDPV producing an impact in the public health of the population. New polio vaccination strategies should be considered to avoid future VDPV cases and to be aligned WHO end- game strategies.
Page 1 and 2:
When citing these abstracts please
Page 3 and 4:
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204: When citing these abstracts please
Page 253: When citing these abstracts please
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
show all

14th ICID - Poster Abstracts - International Society for Infectious ...

Create successful ePaper yourself

Delete template?

Save as template?